Business
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026February 10, 2026 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be delivered at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026 (February 19-22, 2026, Rancho Mirage, CA, U.S.A.
About this update from Nicox Sa
[{"type":"image","alt":"NICOX SA","displaySize":"","headline":null,"caption":"NICOX SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":177,"url":"https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rPuxYymeI_hpr5ShJmv9pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8","width":290,"height":177}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:612.47px;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Press Release ","length":13,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:612.47px;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026","length":105,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:612.47px;vertical-align:top;","val":[{"type":"text","content":"February 10, 2026 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be delivered at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026 (February 19-22, 2026, Rancho Mirage, CA, U.S.A.). “The opportunity to present data from our phase 3 studies with NCX 470, including two high-profile podium presentations, at the upcoming American Glaucoma Society (AGS) Annual Conference highlights the enormous strides Nicox has made to confirm the medical effectiveness of this novel product. The recognition comes at an important time as we prepare the regulatory submissions for NCX 470 in the U.S. and China with our licensees, Kowa and Ocumension, respectively,” said Doug Hubatsch, EVP and Chief Scientific Officer of Nicox. “The AGS conference offers an opportunity for more detailed analysis of data supporting the efficacy, safety, and mechanism of action of NCX 470 to be presented to glaucoma specialist eyecare practitioners at a leading event by well-known and respected Key Opinion Leaders.”AGS 2026 Annual Meeting – February 19 to February 2...